Sentiment-Signal
25,3
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | d Executive Officers The information set forth in Item 5.02 of this Current Report on Form 8-K under the heading “Appoin |
| 10.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n 13(a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 11.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
Stammdaten
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Unternehmen & Branche
| Name | Jade Biosciences, Inc. |
|---|---|
| Ticker | JBIO |
| CIK | 0001798749 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 751,7 Mio. USD |
| Beta | 1,03 |
| Dividendenrendite | 2,40 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -127,410,000 | -3.19 | 349,781,000 | 332,518,000 | |
| 2025-09-30 | 10-Q | -25,175,000 | -0.48 | 202,450,000 | 179,346,000 | |
| 2025-06-30 | 10-Q | -32,134,000 | -0.86 | 223,968,000 | 201,556,000 | |
| 2025-03-31 | 10-Q | -38,169,000 | -0.09 | 77,533,000 | -83,510,000 | |
| 2024-12-31 | 10-K | -46,979,000 | -14.89 | 72,799,000 | -46,799,000 | |
| 2024-09-30 | 10-Q | -16,277,000 | -5.16 | 90,959,000 | -16,863,000 | |
| 2024-06-30 | 10-Q | -590,000 | -0.19 | 111,694,000 | -589,000 | |
| 2024-03-31 | 10-Q | -23,186,000 | -0.83 | 106,821,000 | 90,904,000 | |
| 2023-12-31 | 10-K | -75,521,000 | -2.87 | 127,418,000 | 109,456,000 | |
| 2023-09-30 | 10-Q | -19,563,000 | -0.71 | 140,876,000 | 125,723,000 | |
| 2023-06-30 | 10-Q | -19,025,000 | -0.76 | 155,755,000 | 141,926,000 | |
| 2023-03-31 | 10-Q | -16,520,000 | -0.67 | 124,393,000 | 113,095,000 | |
| 2022-12-31 | 10-K | -51,511,000 | -2.10 | 135,301,000 | 126,743,000 | |
| 2022-09-30 | 10-Q | -13,588,000 | -0.56 | 147,656,000 | 139,138,000 | |
| 2022-06-30 | 10-Q | -11,991,000 | -0.49 | 155,684,000 | 151,053,000 | |
| 2022-03-31 | 10-Q | -10,910,000 | -0.45 | 166,999,000 | 161,947,000 | |
| 2021-12-31 | 10-K | -22,963,000 | -1.87 | 175,363,000 | 172,418,000 | |
| 2021-09-30 | 10-Q | -6,184,000 | -0.26 | 184,125,000 | 179,848,000 | |
| 2021-06-30 | 10-Q | -5,775,000 | 62,434,000 | -21,578,000 | ||
| 2021-03-31 | 10-Q | -2,781,000 | -16,115,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | Frohlich Tom | Director, Officer, Chief Executive Officer | Open Market Purchase | 6,000 | 7.40 | 44,400.00 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.